Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop “plug-and-play” vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID’s new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.
Ophthalmic Complications Observed After Use of GLP-1 Agonists
Though it was not possible to determine causality, a retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide (Ozempic, Wegovy)
February 1, 2025